C.R. Bard

Devices & Diagnostics

Boston Scientific closes Bard EP acquisition

Healthcare business intelligence: Boston Scientific (BSX) closed on its acquisition of C.R. Bard‘s Bard EP Nov. 1. According to a company statement, the addition of Bard’s advanced therapeutic catheters, diagnostic catheters, electrophysiology recording systems and intracardiac access devices will help BSX address the $2.5 billion EP market, which is growing by as much as 10 percent yearly. […]

presented by
presented by
Devices & Diagnostics

C.R. Bard sees double-digit gains in Q2

Vascular and specialty surgical businesses post double-digit gains during the second quarter at C.R. Bard, as the company beats Wall Street estimates with $1.39 EPS. A strong dollar was just enough to bulk up second-quarter results at C.R. Bard Inc. (NYSE:BCR) as the surgical, vascular and oncology technology company out-muscled Wall Street expectations. The Murray […]

Devices & Diagnostics

C.R. Bard acquires SenoRx for $200 million

C.R. Bard Inc. acquires SenoRx Inc. for $200 million, or $11 per share. C.R. Bard Inc. (NYSE:BCR) closed its acquisition of SenoRx Inc. (NSDQ:SENO). The Murray Hill, N.J.-based device conglomerate bought Irvine, Calif.-based SenoRx for about $200 million, or $11 per share. C.R. Bard made the purchase at a 14 percent premium over SenoRx’s May […]

MedCity Influencers

C.R. Bard’s R & D work fuels earnings increase

C.R. Bard Inc. (NYSE:BCR) posted first-quarter sales of $650.8 million, up 9.1 percent compared with $596.4 million during the same period last year. Net income for the Murray Hill, N.J.-based medical device maker rose 7.5 percent to $120.9 million, or $1.24 per diluted share, compared with $112.5 million, or $1.10 per diluted share, during Q1 […]